Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Translation of PDGF cardioprotective pathways

Reply to Letter from Drs. Haider and Ashraf

Stem cell therapy in the aging hearts of Fisher 344 rats: Synergistic effects on myogenesis and angiogenesis

Age-Associated Impairment in Tnf-Alpha Cardioprotection from Myocardial Infarction

Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice.

Cellular aging and rejuvenation in ischemic heart disease: a translation from basic science to clinical therapy

Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases

Cell therapy rescues aging-induced beta-1 adrenergic receptor and GRK2 dysfunction in the coronary microcirculation

The Senescent Heart—"Age Doth Wither Its Infinite Variety"

Regression of pathological cardiac hypertrophy: Signaling pathways and therapeutic targets

Abstract 9586: Existence of Small Juvenile Cells in the Aging Bone Marrow Stromal Cells and Their Therapeutic Potential for Ischemic Heart Disease

Revascularization of Ischemic Tissues by Pdgf-Cc Via Effects on Endothelial Cells and Their Progenitors

Aged‐senescent cells contribute to impaired heart regeneration

MAKING UP OR BREAKING UP: THE TORTUOUS ROLE OF PLATELET‐DERIVED GROWTH FACTOR IN VASCULAR AGEING

Targeting senescent cells for vascular aging and related diseases

BDNF-mediated enhancement of inflammation and injury in the aging heart.

Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease

Oxidative stress-induced cellular senescence desensitizes cell growth and migration of vascular smooth muscle cells through down-regulation of platelet-derived growth factor receptor-beta

Abstract 17563: Upregulation of Anti-Oxidant Signal Pathway and Cytokine Release by Inhibition of P16ink4a in Aging Human Cardiac Progenitor Cells

SYNERGISTIC ADIPOSE-DERIVED STROMAL CELLS AND SARPOGRELATE RECOVER THE IMPAIRED ANGIOGENESIS AND INFLAMMATION MODULATORY FUNCTION IN AGED HINDLIMB ISCHAEMIA MICE

Vasoprotective Effect Of Pdgf-Cc Mediated By Hmox1 Rescues Retinal Degeneration